Cypress Bioscience Inc

Cypress Bioscience — Investor Presentation (July 2010)

36 slides from Cypress Bioscience's investor presentation, Jul 12, 2010

  1. Slide 1: Investor Presentation Summer 2010

    Investor Presentation Summer 2010

  2. Slide 2: Forward looking statements

    2 This presentation may contain certain forward-looking statements concerning the progress and development of the Company and its technology and products, including but not limited to its fibromyalgia program, drug development pipeline, and its personalized medicine services. Actual results could di

  3. Slide 3: Overview

    Overview 3 Cypress has a rich history of CNS expertise and clinical development success While we have managed to build some value in our attempt to transition to the commercial stage, we have come to the conclusion that our commercial business is not likely to provide a source of sustainable competi

  4. Slide 4: Experience and expertise

    Experience and expertise Cypress' drug development team has deep expertise in psychiatry, neuropharmacology, and clinical trial methodology Combined 100+ years of clinical development experience Successful approvals and label expansions in: Devices Diagnostics NCEs Peptides Biologics 4 July, 2010

  5. Slide 5: Cypress: History of clinical success – PROSORBA column

    Cypress: History of clinical success 5 PROSORBA column July, 2010

  6. Slide 6: Prosorba: Approval for RA

    PROSORBA column Approved for Rx of RA Sold to Fresenius 1999 2001 Successfully designed and ran the 1st sham controlled device trial resulting in approval of the Prosorba column for treatment of RA in 1999 Successfully divested Prosorba in 2001 Prosorba(tm): Approval for RA 6

  7. Slide 7: Cypress: History of clinical success – Milnacipran

    Cypress: History of clinical success 7 PROSORBA column Milnacipran July, 2010

  8. Slide 8: Savella for FMS: Efficient drug development in a novel indication

    2001 2002 2003 2004 2005 2006 2007 2008 2009 1997 Cypress licenses Milnacipran from Pierre Fabre for FM Pierre Fabre receives approval for milnacipran as a treatment for a non-pain condition - Now approved in over 50 countries around the world Phase 2 Study N = 125 2nd Phase 3 Study (MLN-MD-02) N =

  9. Slide 9: Cypress: History of clinical success – CNS Proof-of-Concept studies

    Cypress: History of clinical success 9 PROSORBA column Milnacipran CNS Proof-of-Concept (POC) studies July, 2010

  10. Slide 10: Highly efficient POC program in challenging indications

    Highly efficient POC program in challenging indications Time (months) 0 48 12 36 24 Cost ($M) 0 40 35 30 25 20 15 10 5 July, 2010 10 * Longman, IN VIVO, 2007

  11. Slide 11: Overview

    Overview 11 Cypress has a rich history of CNS expertise and clinical development success While we have managed to build some value in our attempt to transition to the commercial stage, we have come to the conclusion that our commercial business is not likely to provide a source of sustainable compet

  12. Slide 12: Cypress: Commercial strategy

    Cypress: Commercial strategy 12 FRX co-promote* Rheumatology (AviseSM) Dx Net Loss: ~$2M/yr Potential synergy July, 2010 Cypress' Sales Force (N= 100 reps + 15 mgmt) Net Loss: ~$9M/yr * 15% flat royalty off of sales (co-promote notwithstading) + subsidy (~65%) of sales force overhead based on number

  13. Slide 13: Savella: Analysts' projections – Value created $100-200M

    13 Value created*: $100-200M * Includes projections by external analysts' reports about Cypress and Forest and reflects the work product of those analysts and not Cypress or Forest, converted to calendar year. Based on a 15% royalty, and a 20% discount rate. Peak sales of $250M - $450M within the an

  14. Slide 14: Cypress: Commercial strategy

    Cypress: Commercial strategy 14 FRX co-promote* Rheumatology (AviseSM) Dx Net Loss: ~$2M/yr Potential synergy July, 2010 Cypress' Sales Force (N= 100 reps + 15 mgmt) Net Loss: ~$9M/yr * 15% flat royalty off of sales (co-promote notwithstading) + subsidy (~65%) of sales force overhead based on number

  15. Slide 15: Avise performance

    Covpress: Avise performance Cypress Dx Product Net Revenue (2,000,000) 2011 2012-2013 2014-2015 201620172018 2019-2020 2021 (4,000,000) Avice PG EE Avise MCV EELCB-CAPs ~®-Total OpEx ——Operating Loss/Profit = Portfolio NPV: $12-27MM (discount rate 30% - 15%) » Net Revenue based on collection rates f

  16. Slide 16: What has led us to this conclusion?

    What has led us to this conclusion? 16 Rx: Difficult environment to acquire complementary commerical products at a reasonable price Dx: Sales of current products did not meet expectations (based on combination of demand and reimbursement), and synergies with Rx did not improve Cypress' economics Pla

  17. Slide 17: Overview

    Overview 17 Cypress has a rich history of CNS expertise and clinical development success While we have managed to build some value in our attempt to transition to the commercial stage, we have come to the conclusion that our commercial business is not likely to provide a source of sustainable compet

  18. Slide 18: CNS overview

    CNS overview CNS is a large market today CNS drugs, generated $121B in worldwide sales in 2009* Large unmet needs in multiple areas 18 July, 2010 Several large pharmas are pulling out of or reducing their focus on CNS * NeuroInsights, The Neurotechnology Industry 2010 Report(tm)

  19. Slide 19: Cypress' revised mission and plan

    Cypress' revised mission and plan Mission: Develop innovative drugs that target large unmet clinical needs for patients suffering from a variety of disorders of the central nervous system Plan: Establish a leading portfolio of CNS assets, all of which will meet the following criteria: Address a larg

  20. Slide 20: In-licensing of CYP-1020

    In-licensing of CYP-1020* Unmet need - Cognitive deficits main predictor of long-term outcome, at least ~80% of patients with schizophrenia are affected Well-characterized - Based on known molecule (perphenazine) with robust P2b data Innovative - Potential to be 1st antipsychotic with pro-cognitive

  21. Slide 21: Cognitive impairment in schizophrenia

    Cognitive impairment in schizophrenia Cognitive Impairment (CI) is a core deficit in schizophrenia: If defined as a failure to meet one's expected level of cognitive functioning, nearly all patients with schizophrenia would qualify as cognitively impaired (Keefe, 2004) Major determinant of poor func

  22. Slide 22: In-licensing of CYP-1020

    In-licensing of CYP-1020 Unmet need - Cognitive deficits main predictor of long-term outcome, at least ~80% of patients with schizophrenia are affected Well-characterized - Based on known molecule (perphenazine) with robust P2b data Innovative - Potential to be 1st antipsychotic with pro-cognitive e

  23. Slide 23: CYP-1020: Well-characterized molecule

    CYP-1020: Well-characterized molecule Perphenazine: 1st generation antipsychotic with a 2nd generation efficacy and tolerability profile (CATIE; Lieberman et al., 2005; Keefe et al., 2007) 23 July, 2010 GABA: Clear role in cognitive dysfunction in schizophrenia (e.g., Lewis 2009) GABAA antagonists b

  24. Slide 24: In-licensing of CYP-1020

    In-licensing of CYP-1020 Unmet need - Cognitive deficits main predictor of long-term outcome, at least ~80% of patients with schizophrenia are affected Well-characterized - Based on known molecule (perphenazine) with robust P2b data Innovative - Potential to be 1st antipsychotic with pro-cognitive e

  25. Slide 25: CYP-1020: Innovative, first-in-class potential

    CYP-1020: Innovative, first-in-class potential To date, no pharmacological therapy has succeeded in producing clinically relevant improvements in cognition in a regulatory context, either as a primary or adjunctive agent Multiple drugs in development, most focused on ?7 nicotinic agonism (e.g., TC-5

  26. Slide 26: EAGLE P2b trial overview

    EAGLE P2b trial overview Double blind, multi-center, 6-week study Designed to determine the efficacy, safety and tolerability of BL-1020 in hospitalized patients with acute exacerbation of schizophrenia Full GCP trial conducted under U.S. FDA IND at 40 sites in the US, Europe and India 363 patients

  27. Slide 27: PANSS total scores: Change from baseline

    PANSS total scores: Change from baseline 27 (CHART) July, 2010

  28. Slide 28: Brief Assessment of Cognition in Schizophrenia (BACS)

    Brief Assessment of Cognition in Schizophrenia (BACS)* Includes 6 tests that measure 6 cognitive domains Approximately 30 min to administer Composite score has high test-retest reliability in patients with schizophrenia 28 Cognitive Domain Test Motor speed Token Motor Task Attention and processing s

  29. Slide 29: BACS total scores: Change from baseline

    BACS total scores: Change from baseline 29 (CHART) July, 2010

  30. Slide 30: BACS subscale scores

    BACS subscale scores 30 July, 2010

  31. Slide 31: In-licensing of CYP-1020

    In-licensing of CYP-1020 Unmet need - Cognitive deficits main predictor of long-term outcome, at least ~80% of patients with schizophrenia are affected Well-characterized - Based on known molecule (perphenazine) with robust P2b data Innovative - Potential to be 1st antipsychotic with pro-cognitive e

  32. Slide 32: CYP-1020: Milestones

    CYP-1020: Milestones 32 July, 2010 2010 2010 2010 2011 2011 2011 2011 2012 2012 2012 2012 2013 2013 2013 2013 2014 2014 2014 2014 2015 2015 2015 2015 q2 q3 q4 q1 q2 q3 q4 q1 q2 q3 q4 q1 q2 q3 q4 q1 q2 q3 q4 q1 q2 q3 q4 P2b ~$15M ~$15M ~$15M ~$15M ~$15M ~$15M ~$15M P3-1 P3-2 P3-OL NDA NDA submission

  33. Slide 33: CYP-1020: Key risks

    CYP-1020: Key risks EAGLE P2b trial was 6-weeks - FDA requires cognition finding at 6-months Open-label 12-week data from EAGLE shows continuing separation between 1020 and risperidone on cognition EAGLE P2b trial used BACS to measure cognition - FDA requires the MCCB 33 July, 2010 Components of the

  34. Slide 34: CYP-1020 deal terms

    CYP-1020 deal terms* $30M upfront Anticipated R&D commitment for next trial of $15M over ~2 years Total clinical and regulatory milestones of up to $160M through to approval The majority of which are dependent on success in improving cognition Commercial milestones of up to $85M Additional $90M for

  35. Slide 35: We have financial wherewithal to execute on our strategy

    35 We have financial wherewithal to execute on our strategy We expect to add more programs this year to achieve our stated goal of building the best CNS pipeline in industry We expect that all programs will meet the objectives outlined above (i.e., unmet need, well-characterized, innovative, milesto

  36. Slide 36: We have financial wherewithal to execute on our strategy

    36 We have financial wherewithal to execute on our strategy Expect to end 2010 with ~$95 million Shares outstanding: 38M basic, 46M fully diluted No debt July, 2010

Cypress Bioscience — Investor Presentation (July 2010) on 6ix